Probiotic-Induced Tolerogenic Dendritic Cells : A Novel Therapy for Inflammatory Bowel Disease?
Inflammatory bowel diseases (IBDs) are immune-mediated, chronic relapsing diseases with a rising prevalence worldwide in both adult and pediatric populations. Treatment options for immune-mediated diseases, including IBDs, are traditional steroids, immunomodulators, and biologics, none of which are capable of inducing long-lasting remission in all patients. Dendritic cells (DCs) play a fundamental role in inducing tolerance and regulating T cells and their tolerogenic functions. Hence, modulation of intestinal mucosal immunity by DCs could provide a novel, additional tool for the treatment of IBD. Recent evidence indicates that probiotic bacteria might impact immunomodulation both in vitro and in vivo by regulating DCs' maturation and producing tolerogenic DCs (tolDCs) which, in turn, might dampen inflammation. In this review, we will discuss this evidence and the mechanisms of action of probiotics and their metabolites in inducing tolDCs in IBDs and some conditions associated with them.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
International journal of molecular sciences - 22(2021), 15 vom: 31. Juli |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Baradaran Ghavami, Shaghayegh [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Crohn’s disease |
|---|
| Anmerkungen: |
Date Completed 08.09.2021 Date Revised 08.09.2021 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/ijms22158274 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329053043 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329053043 | ||
| 003 | DE-627 | ||
| 005 | 20231225204252.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ijms22158274 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1096.xml |
| 035 | |a (DE-627)NLM329053043 | ||
| 035 | |a (NLM)34361038 | ||
| 035 | |a (PII)8274 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Baradaran Ghavami, Shaghayegh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Probiotic-Induced Tolerogenic Dendritic Cells |b A Novel Therapy for Inflammatory Bowel Disease? |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.09.2021 | ||
| 500 | |a Date Revised 08.09.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Inflammatory bowel diseases (IBDs) are immune-mediated, chronic relapsing diseases with a rising prevalence worldwide in both adult and pediatric populations. Treatment options for immune-mediated diseases, including IBDs, are traditional steroids, immunomodulators, and biologics, none of which are capable of inducing long-lasting remission in all patients. Dendritic cells (DCs) play a fundamental role in inducing tolerance and regulating T cells and their tolerogenic functions. Hence, modulation of intestinal mucosal immunity by DCs could provide a novel, additional tool for the treatment of IBD. Recent evidence indicates that probiotic bacteria might impact immunomodulation both in vitro and in vivo by regulating DCs' maturation and producing tolerogenic DCs (tolDCs) which, in turn, might dampen inflammation. In this review, we will discuss this evidence and the mechanisms of action of probiotics and their metabolites in inducing tolDCs in IBDs and some conditions associated with them | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Crohn’s disease | |
| 650 | 4 | |a dendritic cells | |
| 650 | 4 | |a inflammatory bowel diseases | |
| 650 | 4 | |a mucosal tolerance | |
| 650 | 4 | |a probiotics | |
| 650 | 4 | |a ulcerative colitis | |
| 700 | 1 | |a Asadzadeh Aghdaei, Hamid |e verfasserin |4 aut | |
| 700 | 1 | |a Sorrentino, Dario |e verfasserin |4 aut | |
| 700 | 1 | |a Shahrokh, Shabnam |e verfasserin |4 aut | |
| 700 | 1 | |a Farmani, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Ashrafian, Fatemeh |e verfasserin |4 aut | |
| 700 | 1 | |a Dore, Maria Pina |e verfasserin |4 aut | |
| 700 | 1 | |a Keshavarz Azizi Raftar, Shahrbanoo |e verfasserin |4 aut | |
| 700 | 1 | |a Mobin Khoramjoo, Seyed |e verfasserin |4 aut | |
| 700 | 1 | |a Zali, Mohammad Reza |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of molecular sciences |d 2008 |g 22(2021), 15 vom: 31. Juli |w (DE-627)NLM185552161 |x 1422-0067 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2021 |g number:15 |g day:31 |g month:07 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/ijms22158274 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2021 |e 15 |b 31 |c 07 | ||